HC Wainwright & Co. Maintains Buy on Cogent Biosciences, Raises Price Target to $56

Benzinga · 2d ago
HC Wainwright & Co. analyst Robert Burns maintains Cogent Biosciences (NASDAQ:COGT) with a Buy and raises the price target from $55 to $56.